Synthesis of New Fluorine Containing Triazolo- and Tetrazolopyrimidines

Arcady L. Krasovsky, Andrew M. Moiseev, Valentine G. Nenajdenko,* Elizabeth S. Balenkova

Department of Chemistry, Moscow State University, 119899 Moscow, Russia Fax +7(095)9328846; E-mail: Nen@acylium.chem.msu.su *Received 5 February 2002*

Abstract: The reaction of 1,1,1-trifluoro-4-(sulfonyl)-but-3-ene-2,2-dioles **1a,b** with corresponding aminoazoles was investigated. A new simple and efficient way for the regioselective synthesis of 5-CF₃ or 7-CF₃ triazolo- and tetrazolopyrimidines is described.

Key words: cycloaddition, heterocycles, triazolopyrimidine, tetrazolopyrimidine, sulfones

Fluorine containing heterocyclic compounds are a subject of continuous interest^{1,2} due to their potent pharmacological properties. Some fluorinated pyrimidines were clinically evaluated as valuable anticancer agents.³ It is known that incorporation of a fluorine atom or CF₃- group into bioactive molecule leads to increased lipid solubility and thereby enhances the rate of absorption and transport of that substance in vivo.¹Also, many triazolopyrimidines have shown significant herbicidal,⁴ fungicidal⁵ activity and are well-known as new cardiovascular agents⁶. The reported methods for the synthesis of substituted azolopyrimidines usually involves cyclocondensation of aminotriazoles⁵⁻¹² or aminoterazoles^{8,13} with three carbon 1,3-electrophilic fragments.¹⁴ A drawback of these approaches is the formation of the mixture of isomers from the reaction of non-symmetrical systems with aminoazoles.^{4,12} Paudler at al. obtained mixtures when treating triazolopyrimidine with phenyllithium.¹⁵ Novel methods for the construction of the triazolopyrimidines nucleus involving reactions of vinylogous iminium salts and related analogs with 3-amino-1,2,4-triazoles have been reported last year.¹⁶ An alternative synthetic route to different triazolopyrimidines is the reaction of 2-hydrazinopyrimidine with acylating agents and also the Dimroth-like rearrangement of triazolo[4,3-a]pyrimidines to triazolo[1,5-a]pyrimidines in acid or alkali.5,17

Thus, there is a limited amount of the regiospecific synthesis of 7- and 5-substituted azolopyrimidines.^{7,16} There is a definite need to develop new methods for the regiospecific synthesis of this class of compounds.

In recent work, we have prepared some β -trifluoroacetylvinylsulfones.¹⁸ We have found that alkenes **1a**,**b** are very reactive electrophiles, reacting with heteroarenes such as pyrrole, indole and furan.¹⁹ Also, we have recently described a new simple and efficient way for the regiospecific formation of CF₃-containing imidazo[1,2-*a*]pyridines,²⁰ pyrazolo[1,5-*a*]pyrimidines,²¹ 6,7-dihydro-5*H*-1,3,4-thiadiazolo[3,2-*a*]pyrimidines,²² and 6,7-dihydro-5*H*-thiazolo[3,2-*a*]pyrimidines²³ by the reaction of sulfones **1a,b** with various aminoheterocycles. It was therefore considered that the reaction of diols **1a,b** with 3-amino-1,2,4-triazoles and 5-aminotetrazole might result in improved regioselectivity yielding only one regioisomer under a particular reaction condition.

Treatment of **1a**,**b** with different 3-amino-1,2,4-triazoles and 5-aminotetrazole in acetic acid at reflux gave a mixture of cycloadducts **2a**–**k** and **3a**–**k** in 70–90% isolated yields (Scheme 1, Table 1). It is worth mentioning, that in water, under reflux, no significant difference of the ratio of regioisomer was observed. The reaction of **1a**,**b** with aminotriazoles at room temperature afforded only 5% conversion after 10 days. It should be noted that the yields and ratio of 5- and 7-CF₃ substituted azolopyrimdines do not depend significantly on reagents **1a** or **1b**. Moreover, the reaction with triazoles bearing both aliphatic and aromatic substituents as a rule gives a mixture of isomeric azolopyrimdines. Only in the case of aryltriazoles **f**–**h** the highly regioselectively formation of 7-CF₃ azolopyrimdines is observed.





Nevertheless, simple modification of reaction conditions allowed us to obtain 5-CF₃ triazolo[1,5-*a*]pyrimidines **2** as a pure regioisomer. We have observed that the reaction of sulfones **1a,b** with 3-amino-1,2,4-triazoles in acetonitrile at room temperature yields exclusively the 5-CF₃ isomer of tetrahydro[1,2,4]triazolo[1,5-*a*]pyrimidine (**4**). Compound **4** precipitated from the reaction mixture. None of the isomeric 7-CF₃ isomer could be detected in the reaction. Moreover, this reaction proceeds stereoselectively to give **2**, the only diastereomer of triazolo[1,5-*a*]pyrimidines having diaxially oriented sulfonyl and hydroxyl groups. Earlier, we observed the same arrangement of these groups in analogous tetrahydropyrimidines system^{22,23} and have confirmed this by X-ray crystallography.²² We presume that, it is connected with the formation

Synthesis 2002, No. 7, 21 05 2002. Article Identifier: 1437-210X,E;2002,0,07,0901,0905,ftx,en;P00302SS.pdf. © Georg Thieme Verlag Stuttgart · New York ISSN 0039-7881

 Table 1
 Yields and Regioisomeric Ratio of Cycloadducts 2 and 3

Х	Entry	Method	from 1a		from 1b	
			2:3 ^a	Yield %	2:3 ^a	Yield %
НС	a	Α	100:10	83	100:44	80
		В	100:15	86	100:50	82
MeC	b	В	88:100	80	95:100	75
CF ₃ C	c	В	28:100	74	59:100	70
(1-Ad)C	d	В	10:100	78	38:100	74
t-BuC	e	В	15:100	76	44:100	76
PhC	f	В	5:100	83	24:100	78
4-MeOC ₆ H ₄ C	g	В	0:100	70	3:100	72
4-ClC ₆ H ₄ C	h	В	2:100	93	13:100	90
2-BrC ₆ H ₄ C	i	В	19:100	81	37:100	76
MeOOCC	j	В	100:7	87	100:23	86
Ν	k	В	3:100	72	16:100	72

^a Structure and ratios of products were determined by ¹H NMR

of intramolecular hydrogen bond between sulfonyl and hydroxyl group in **4**.

Further aromatization of **4** at reflux in acetic acid provides $5\text{-}CF_3$ triazolo[1,5-*a*]pyrimidines **2** as one regioisomer quantitatively. We have also investigated one-pot synthesis of $5\text{-}CF_3$ triazolo[1,5-*a*]pyrimidines **2** in acetonitrile at reflux (method **C**, Scheme 2, Table 2). This approach provides a simple way to obtain $5\text{-}CF_3$ triazolo[1,5-*a*]pyrimidines. We reason that, in this case the reaction is autocatalyzed by the eliminated sulfinic acid. In spite of slighly lower yields, the one-pot technique is attractive due to its simplicity.



Scheme 2

Introduction of a polar group, such as the carboxylic acid, at position 2 of triazolopyrimidines resulted in a greater solubility of new potential biologically active CF₃- containing azolopyrimdines and therefore has increased inter-

Yields of Cycloadducts 4, and 2 Obtained by Method C Table 2 Х from 1a from 1b entry Yield % Yield % entry HC 4a 4b 85 86 PhC 4c 88 4d 90 HC 2a 70 2a 65 (1-Ad)C 2d 68 2d72 t-BuC 2e 64 2e 66 PhC 2f 75 2f70

61

65

est in this class of compounds.9 In the reaction of the sulfones **1a**,**b** with 3-amino-1*H*-1,2,4-triazole-5-carboxvlic acid in acetic acid under reflux, a mixture of triazolopyrimidines 2a,3a was obtained in good yield instead of the expected product. Moreover, the ratio of isomers 2a:3a is the same as for the reaction with unsubstituted 3amino-1,2,4-triazole. We believe that decarboxylation of 3-amino-1H-1,2,4-triazole-5-carboxylic acid precedes the step of heterocyclization. To avoid decarboxylation, we performed the reaction of 1a,b with the corresponding ester of [1,2,4]triazolo[1,5-*a*]pyrimidine-2-carboxylic acid. Initially formed cycloadducts 2j,3j can be smoothly converted to [1,2,4]triazolo[1,5-*a*]pyrimidine-2-carboxylic acid 21,31 (Scheme 3) by hydrolysis with lithium hydroxide in methanol (method **D**). Alternatively, carboxylic acid 2l can be prepared by the reaction of sulfones 1a,b with the 3-amino-1H-1,2,4-triazole-5-carboxylic acid in water at reflux (method A).





2,4-Cl₂C₆H₃C

2-BrC₆H₄C

2m

2i

The regiochemistry of 5- and 7-CF₃ substituted compounds **2**,**3** can be established by ¹H NMR spectroscopy. The cycloadducts having 5-CF₃-substitution have J_{HH}^3 6.9–7.3 Hz, while those with a 7-CF₃-substitution have J_{HH}^3 4.2–4.8 Hz. (Scheme 4).^{7,17}

63

66

2m

2i

3a-i

5

2a-l Scheme 4

Two types of heterocyclization in reactions of 1.3-bielectrophiles with aminotriazoles to form triazolo[1,5-a]pyrimidines or triazolo[4,3-a]pyrimidines system are described in literature. Calculations of total energy of basic states showed that triazolo[1,5-a]pyrimidines are more isomeric triazolo[4,3-*a*]pyrimidines.²⁴ stable than Kawase²⁵ and Bouillon²⁶ showed NH₂-4-N ring atom cyclization with the formation of [1,2,4]triazolo[4,3-a]pyrimidine ring by only an NOE experiment²⁵ or by questionable comparison of UV-VIS and ¹³C NMR data. Others attribute the formation of [1,2,4]triazolo[1,5-a]pyrimidine in the reaction of 1,2,4-triazol-3-amines to 1,3bielectrophiles and some authentic X-ray diffraction analysis¹² or by independent synthesis.^{7,8b,16} In order to confirm the formation of the pair of 2,3 isomers instead of isomers of 5, we performed an NOE experiment for the mixture of 2b:3b (95:100) isomers and have not observed this effect in both isomers. Therefore, at least in our case, the formation of triazolo[1,5-a]pyrimidines system takes place.

In summary, the reaction of 1,1,1-trifluoro-4-(sulfonyl)but-3-ene-2,2-dioles **1a,b** with 3-amino-1,2,4-triazoles and 5-aminotetrazole was investigated. The reaction in acetic acid leads to the mixture of 5- and 7-CF₃- isomers. We have developed a novel regiospecific technique with simple experimental layout which allows for the preparation of pure 5-CF₃-azolo[1,2-*a*]pyrimidines in high yields.

Melting points were determined in sealed capillaries and are uncorrected. NMR spectra were recorded on Varian VXR-400 spectrometer with TMS as an internal standard. The IR spectra were obtained with UR-20 spectrometer as films. Column chromatography was performed on silica gel (63–200 mesh, Merck). All solvents used were dried and distilled according to standard procedures. Silica gel Merck 60 and Merck $60F_{254}$ plates were used for conventional and analytical (TLC) chromatography, respectively.

Azolopyrimidines 2,3; General Procedure

To a solution of vinyl sulfone **1a,b** (1 mmol) in H₂O (10 mL) (method **A**), in AcOH (5 mL) (method **B**) or in CH₃CN (method **C**) the corresponding aminoazole (1.1 mmol) was added. The mixture was stirred at reflux at the appropriate time. Removal of the solvent under reduced pressure afforded products, which were purified by column chromatography over silica gel using CH₂Cl₂ as eluent.

5-(Trifluoromethyl) [1,2,4]triazolo[1,5-*a*]pyrimidine-2-carbox-ylic acid (2l)

Method A: To a solution of vinylsulfone **1a,b** (1 mmol) in H_2O (25 mL) the 3-amino-1*H*-1,2,4-triazole-5-carboxylic acid (1.1 mmol) was added. The mixture was stirred for 10 h at reflux. The solution was cooled and the pH adjusted to 2.0 with HCl (10%). The white

precipitate of 2l was filtered, washed by $H_2O~(2\times 5~mL)$ and air dried. Yield 53%.

Method **D**: 1. As the common technique. 2. To a solution of methyl [1,2,4]triazolo[1,5-*a*]pyrimidine-2-carboxylate (**2j**, 0.5 mmol) in MeOH (5 mL) the solution of LiOH (1.1 equiv) in MeOH was added. The mixture was stirred at r.t. for 24 h. Removal of the solvent under reduced pressure afforded products, which was dissloved in H₂O (5 mL) and the pH adjusted to 2.0 with HCl (10%). The white precipitate of **2l** was filtered, washed by H₂O (2 × 5 mL) and dried on air; yield 71%; white solid; mp 120–123 °C.

IR: 1770 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 7.78 (1 H, d, CH-6, *J* = 7.1 Hz), 9.24 (1 H, d, CH-7, *J* = 7.1 Hz).

¹³C NMR (100 MHz, DCl₃) δ = 110.5, 128.9 (q, *J* = 277.0 Hz, CF₃), 142.3, 153.7, 156.5, 158.3, 159.9 (q, *J* = 40, 1 Hz, C-CF₃).

Anal. Calcd for $C_{14}H_{13}F_3O_3S$: C, 36.22; H, 1.30. Found: C, 36.11; H, 1.19.

4,5,6,7-Tetrahydro[1,2,4]triazolo[1,5-*a*]pyrimidines (4)

To a solution of vinylsulfone **1a**,**b** (1 mmol) in CH₃CN (7 mL) the corresponding aminoazoles (1.1 mmol) was added. The mixture was stirred for 12 h at r.t. The precipitate was filtered, washed by CH₃CN (2×3 mL) and dried on air.

7-(Phenylsulfonyl)-5-(trifluoromethyl)-4,5,6,7-tetrahydro-[1,2,4]triazolo[1,5-*a*]pyrimidin-5-ol (4a)

White solid; mp 136–138 °C.

IR: 2920, 1374 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 2.29 (1 H, dd, CH-6, *J* = 12.4, 13.5 Hz), 2.63 (1 H, dd, CH-6, *J* = 4.8, 13.5 Hz), 5.62 (1 H, dd, CH-7, *J* = 4.8, 12.4 Hz), 7.40 (1 H, m, Ph), 7.70 (2 H, m, Ph), 7.79 (2 H, m, Ph), 9.02 (1 H, br s, CH-2).

¹³C NMR (100 MHz, CDCl₃): 26.7, 67.8, 79.5 (COH, *J* = 41.2 Hz), 123.7 (CF₃, *J* = 285.8 Hz), 129.7, 132.0, 133.0, 140.6, 150.6, 152.3.

Anal. Calcd for $C_{12}H_{11}F_3N_4O_3S$: C, 41.38; H, 3.18. Found: C, 41.21; H, 3.19.

7-(Methylsulfonyl)-5-(trifluoromethyl)-4,5,6,7-tetrahydro-[1,2,4]triazolo[1,5-a]pyrimidin-5-ol (4b) White solid; mp 151–153 °C.

IR: 2924, 1382 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 2.10 (1 H, m, CH-6), 2.67 (1 H, m, CH-6), 3.34 (3 H, s, CH₃), 5.90 (1 H, br t, CH-7, *J* = 6.7 Hz), 9.0 (1 H, br s, CH-2).

¹³C NMR (100 MHz, DCl₃): δ = 26.4, 41.2, 67.7, 79.1 (COH, J = 41.4 Hz), 124.0 (CF₃, J = 286.0 Hz), 150.6, 152.3.

Anal. Calcd for $C_{79}F_3N_4O_3S$: C, 29.37; H, 3.17. Found: C, 29.29; H, 3.12.

2-Phenyl-7-(phenylsulfonyl)-5-(trifluoromethyl)-4,5,6,7-tetrahydro[1,2,4] triazolo[1,5-*a***]pyrimidin-5-ol (4c) White solid; mp 177–179 °C.**

IR: 2921, 1373 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 2.24 (1 H, dd, CH-6, *J* = 12.4, 13.4 Hz), 2.60 (1 H, dd, CH-6, *J* = 4.8, 13.4 Hz), 5.60 (1 H, dd, CH-7, *J* = 4.8, 12.4 Hz), 7.40 (2 H, m, Ph), 7.48 (2 H, m, Ph), 7.70 (3 H, m, Ph), 7.79 (3 H, m, Ph), 9.11 (1 H, br s, CH-2).

¹³C NMR (100 MHz, CDCl₃): δ = 26.9, 67.7, 79.0 (COH, J = 41.3 Hz), 124.0 (CF₃, J = 284.1 Hz), 129.5, 132.1, 133.0, 133.6, 137.8, 140.1, 140.6, 142.4, 150.6, 152.3.

Table 3	Spectroscopic Data
---------	--------------------

¹ H NMR (DMSO- d_6 /TMS) δ , J (Hz)	¹³ C NMR (DMSO- d_{6} /TMS) δ , J (Hz)	Mp, °C
2a : 7.48 (d, 1 H, <i>J</i> = 7.1 Hz, CH-6), 8.67 (s, 1 H, CH-8), 9.11 (d, 1 H, <i>J</i> = 7.1 Hz, CH-7) 3a : 7.48 (d, 1 H, <i>J</i> = 4.3 Hz, CH-6), 8.66 (s, 1 H, CH-8), 9.01 (d, 1 H, <i>J</i> = 4.3 Hz, CH-5)	Major isomer 2a : 105.5, 119.8 (q, <i>J</i> = 277.1 Hz, CF ₃), 138.8, 150.5 (q, <i>J</i> = 37.0 Hz, C-CF ₃), 154.5, 156.8	128–130
2b : 2.60 (s, 3 H, CH ₃), 7.51 (d, 1 H, <i>J</i> = 7.1 Hz, CH-6), 9.15 (d, 1 H, <i>J</i> = 7.1 Hz, CH-7) 3b : 2.60 (s, 3 H, CH ₃), 7.54 (d, 1 H, <i>J</i> = 4.2 Hz, CH-6), 8.91 (d, 1 H, <i>J</i> = 4.2 Hz, CH-5)	2b : 15.2, 107.5, 120.2 (q, $J = 277.9$ Hz, CF ₃), 139.4, 155.8 (q, $J = 38.3$ Hz, C-CF ₃), 140.4, 156.5 3b : 15.3, 110.0, 123.8 (q, $J = 276.7$ Hz, CF ₃), 149.4 (q, $J = 37.7$ Hz, CCF ₃), 150.8, 154.8, 169.0	142–144
2c : 7.80 (d, 1 H, <i>J</i> = 7.2 Hz, CH-6), 9.39 (d, 1 H, <i>J</i> = 7.2 Hz, CH-7) 3c : 7.84 (d, 1 H, <i>J</i> = 4.5 Hz, CH-6), 9.18 (d, 1 H, <i>J</i> = 4.5 Hz, CH-5)	Major isomer 3c : 110.6, 120.0 (q, <i>J</i> = 274.8 Hz, CF ₃), 121.4 (q, <i>J</i> = 277.2 Hz, CF ₃), 142.9 (q, <i>J</i> = 37.2 Hz, C-CF ₃), 151.0, 151.4 (q, <i>J</i> = 38.0 Hz, C-CF ₃), 154.4	84–86
2d : 1.65–2.18 (m, 15 H, Ad), 7.53 (d, 1 H, <i>J</i> = 7.1 Hz, CH-6), 9.21 (d, 1 H, <i>J</i> = 7.1 Hz, CH-7) 3d : 1.65–2.18 (m, 15 H, Ad), 7.55 (d, 1 H, <i>J</i> = 4.3 Hz, CH-6), 8.92 (d, 1 H, <i>J</i> = 4.3 Hz, CH-5)	Major isomer 3d : 20.7, 29.1, 37.1, 41.8, 109.8, 120.8 (q, <i>J</i> = 277.7 Hz, CF ₃), 140.1, 149.1 (q, <i>J</i> = 38.5 Hz, C-CF ₃), 156.4, 175.3	101–103
2e : 1.46 (s, 9 H, 3 CH ₃), 7.51 (d, 1 H, $J = 7.1$ Hz, CH-6), 9.16 (d, 1 H, $J = 7.1$ Hz, CH-7) 3e : 1.46 (s, 9 H, 3 CH ₃), 7.53 (d, 1H, $J = 4.4$ Hz, CH-6), 8.91 (d, 1 H, $J = 4.4$ Hz, CH-5)	Major isomer 3e : 29.7, 35.7, 109.6, 121.2 (q, <i>J</i> = 277.0 Hz, CF ₃), 140.0, 149.3 (q, <i>J</i> = 37.9 Hz, C-CF ₃), 154.6, 178.1	113–115
2f : 7.54–7.58 (m, 4 H, Ar + CH-6), 8.30–8.33 (m, 2 H, Ar), 9.24 (d, 1 H, <i>J</i> = 7.1 Hz, CH-7) 3f : 7.54–7.58 (m, 3 H, Ar), 7.60 (d, 1 H, <i>J</i> = 4.3 Hz, CH-6), 8.30–8.33 (m, 2 H, Ar), 8.98 (d, 1 H, <i>J</i> = 4.3 Hz, CH-5)	2f : 113.0, 120.2 (q, <i>J</i> = 277.8 Hz, CF ₃), 130.5, 130.9, 135.1, 135.9, 150.4, 157.9, 164.0 (q, <i>J</i> = 40.0 Hz, C-CF ₃), 170.1 3f : 110.7, 118.9 (q, <i>J</i> = 276.6 Hz, CF ₃), 129.0, 130.7, 133.0, 135.8, 150.2, 157.2, 159.4 (q, <i>J</i> = 39.5 Hz, C-CF ₃), 172.8	180–182
2g : 3.85 (s, 3 H, CH ₃), 6.95 (d, 2 H, Ar), 7.54 (d, 1 H, $J = 7.0$ Hz, CH-6), 7.94 (d, 2 H, Ar), 9.18 (d, 1 H, $J = 7.0$ Hz, CH-7) 3g : 3.83 (s, 3 H, CH ₃), 7.05 (d, 2 H, Ar), 7.56 (d, 1 H, $J = 4.4$ Hz, CH-6), 8.21 (d, 2 H, Ar), 8.91 (d, 1 H, $J = 4.4$ Hz, CH-5)	Major isomer 3g : 56.46, 111.2, 116.7, 118.8 (q, <i>J</i> = 280.1 Hz, CF ₃), 129.0, 130.0, 157.6, 158.0, 159.6 (q, <i>J</i> = 41.0 Hz, C-CF ₃), 164.5, 175.7	195–197
2h : 7.55 (d, 2 H, Ar), 7.58 (d, 1 H, <i>J</i> = 6.9 Hz, CH-6), 7.96 (d, 2 H, Ar), 9.23 (d, 1 H, <i>J</i> = 6.9 Hz, CH-7) 3h : 7.55 (d, 2 H Ar), 7.61 (d, 1 H, <i>J</i> = 4.3 Hz, CH-6), 8.27 (d, 2 H, Ar), 8.98 (d, 1 H, <i>J</i> = 4.3 Hz, CH-5)	Major isomer 3h : 111.0, 118.9 (q, <i>J</i> = 277.4 Hz, CF ₃), 129.4, 132.3, 132.8, 135.6, 154.2, 156.6, 159.1 (q, <i>J</i> = 39.7 Hz, C-CF ₃), 170.8	168–170
2i : 7.43 (m, 1 H, Ar), 7.53 (m, 1 H, Ar), 7.62 (d, <i>J</i> = 7.0 Hz, CH- 6), 7.80 (m, 1 H, Ar), 7.96 (m, 1 H, Ar), 9.29 (d, 1 H, <i>J</i> = 7.0 Hz, CH-7) 3i : 7.43 (m, 1 H, Ar), 7.53 (m, 1 H, Ar), 7.64 (d, <i>J</i> = 4.3 Hz, CH- 6), 7.80 (m, 1 H, Ar), 7.96 (m, 1 H, Ar), 9.02 (d, 1 H, <i>J</i> = 4.3 Hz, CH-5)	Major isomer 3i : 110.1, 120.8 (q, <i>J</i> = 275.2 Hz, CF ₃), 129.5, 130.3, 132.9, 133.5, 134.0, 135.9, 141.0, 157.3, 160.2 (q, <i>J</i> = 39.9 Hz, C-CF ₃), 173.7	123–125
2j : 4.00 (s, 3 H, CH ₃), 7.73 (d, 1 H, $J = 7.1$ Hz, CH-6), 9.36 (d, 1 H, $J = 7.1$ Hz, CH-7) 3j : 4.00 (s, 3 H, CH ₃), 7.77 (d, 1 H, $J = 4.4$ Hz, CH-6), 9.11 (d, 1 H, $J = 4.4$ Hz, CH-5)	Major isomer 2j : 54.0, 109.9, 129.7 (q, <i>J</i> = 276.1 Hz, CF ₃), 142.2, 154.9, 156.2, 158.8, 161.3 (q, <i>J</i> = 40.4 Hz, C-CF ₃)	170–171
2k : 7.66 (d, 1 H, <i>J</i> = 7.3 Hz, CH-6), 9.43 (d, 1 H, <i>J</i> = 7.3 Hz, CH-7) 3k : 7.42 (d, 1 H, <i>J</i> = 4.8 Hz, CH-6), 8.81 (d, 1 H, <i>J</i> = 4.8 Hz, CH-5)	Major isomer 3k : 108.7, 121.2 (q, <i>J</i> = 277.0 Hz, CF ₃), 156.2 (q, <i>J</i> = 39.9 Hz, C-CF ₃), 156.2, 162.7	120–122
2m : ^b 7.48 (d, 2 H, Ar), 7.63 (d, 2 H, Ar), 7.82 (d, 1 H, <i>J</i> = 6.9 Hz, CH-6), 7.84 (d, 2 H, Ar), 9.40 (d, 1 H, <i>J</i> = 6.9 Hz, CH-7)	2m : 109.6, 114.3 (q, <i>J</i> = 283.3 Hz, CF ₃), 120.7, 123.7, 128.1, 131.2, 132.9, 134.4, 139.5, 151.7, 155.3 (q, <i>J</i> = 39.7 Hz, C-CF ₃), 162.4	160–162

 a Satisfactory microanalyses were obtained: C \pm 0.28, H \pm 0.25. b In CDCl₃/CF₃COOH.

Anal. Calcd for $C_{18}H_{15}F_{3}N_{4}O_{3}S$: C, 50.94; H, 3.56. Found: C, 51.03; H, 3.49.

2-Phenyl-7-(methylsulfonyl)-5-(trifluoromethyl)-4,5,6,7-tetrahydro[1,2,4] triazolo[1,5-*a*]pyrimidin-5-ol (4d)

White solid; mp 184–186 °C.

IR: 2926, 1384 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 2.18 (1 H, dd, CH-6, *J* = 12.6, 13.3 Hz), 2.67 (1 H, dd, CH-6, *J* = 4.6, 13.3 Hz), 3.32 (3 H, s, CH₃), 5.90 (1 H, dd, CH-7, *J* = 4.6, 12.6 Hz), 7.46 (2 H, m, Ph), 7.69 (1 H, m, Ph), 7.80 (2 H, m, Ph), 9.08 (1 H, br s, CH-2).

¹³C NMR (100 MHz, DCl₃): δ = 26.6, 41.4, 67.7, 80.1 (C-OH, J = 41.0 Hz), 124.2 (CF₃, J = 286.6 Hz), 133.7, 140.4, 140.8, 142.8, 150.6, 152.3.

Anal. Calcd for $C_7H_9F_3N_4O_3S$: C, 29.37; H, 3.17. Found: C, 29.29; H, 3.12.

Azolopyrimidines 2 from 4; General Procedure

The corresponding 4,5,6,7-tetrahydro[1,2,4]triazolo[1,5-*a*]pyrimidine **4** (0.5 mmol) was dissolved in HOAc (10 mL). The mixture was stirred for 1 h under reflux. The solvent was evaporated under reduced pressure. The residue was purified by column chromatography over silica gel using CH_2Cl_2 as eluent; yield 95–98%.

Acknowledgement

Financial support from Russian Fundamental Investigation Foundation (Grants 00-03-32763a and 00-03-32760) is gratefully acknowledged.

References

- (a) Filler, R. In *Fluorine Containing Drugs in* Organofluorine Chemicals and Their Industrial Applications; Pergammon: New York, **1979**, Chapter 6.
 (b) Holland, G. F.; Pereira, J. N. J. Med. Chem. **1967**, 10, 149.
- (2) (a) Rempfler, H.; Duerr, D. EP 337944, **1989**; *Chem. Abstr.* **1990**, *112*, 139043r. (b) Rempfler, H.; Duerr, D.; Thummel, R. C. EP 337943, **1989**; *Chem. Abstr.* **1990**, *112*, 139044s.
- (3) (a) Heidelberg, C. Annu. Rev. Pharmacol. Toxicol. 1967, 7, 10. (b) Duschinsky, R.; Pleven, E.; Heidelberg, C. J. Am. Chem. Soc 1957, 79, 4559. (c) Hillers, S.; Lazdins, A.; Veinbergs, K.; Sidorov, B. US Patent 4039546, 1977; Chem. Abstr. 1977, 87, 168342h.
- (4) (a) Kleschick, W.; Her, R.; Gerwick, B.; Monte, W.; Pearson, N.; Costales, M.; Meikle, R. US Patent 4740233, **1988**. (b) Selby, T.; Andrea, T.; Denes, L.; Finkelstein, B.; Fuesler, T.; Smith, J. In *Synthesis and Chemistry of Agrochemicals III*; Baker, D.; Fenyes, J.; Steffens, J., Eds.; American Chemical Society: Washington DC, **1992**, 91– 102.

- (5) Popova, L. M.; Trishina, A. U.; Vershilov, S. V.; Ginak, A. L.; Maksimov, B. N. *J. Fluorine Chem* **1999**, *96*, 51.
- (6) Novinson, T.; Springer, R. H.; O'Brien, D. E.; Scholten, M. B.; Miller, J. P.; Robins, R. K. J. Med. Chem. 1982, 25, 420; and references therein.
- Monte, W. T.; Kleschick, W. A.; Meikle, R. W.; Snider, S. W.; Bordner, J. J. Heterocycl. Chem. 1989, 26, 1393.
- (8) (a) Allen, C. F. H.; Beilfuss, H. R.; Burness, D. M.; Reynolds, G. A.; Tinker, J. F.; Van Allan, J. A. J. Org. Chem. 1959, 24, 796. (b) Bajwa, J. S.; Sykes, P. J. J. Chem. Soc., Perkin Trans. I 1979, 3085.
- (9) Okabe, T.; Bhooshan, B.; Novinson, T.; Hillyard, I. W.; Garner, G. E.; Robins, R. K. J. Heterocycl. Chem. 1983, 20, 735.
- (10) Chambers, V. C. J. Am. Chem. Soc. 1960, 82, 605.
- (11) Hori, M.; Tanaka, K.; Kataoka, T.; Shimizu, H.; Imai, E.; Kimura, K.; Hashimoto, Y. J. Chem. Soc., Perkin Trans. I 1985, 2333.
- (12) Kleschick, W. A.; Bordner, J. J. Heterocycl. Chem. **1989**, 26, 1489.
- (13) (a) Buelow, C. Chem. Ber. 1909, 42, 4429.
 (b) Bachkovskij, I. P.; Chuiguk, V. A. Ykr. Khim. Z. 1987, 53, 319. (c) Bajwa, J. S.; Sykes, P. J. J. Chem. Soc., Perkin Trans. I 1980, 1019. (d) Russ, T.; Bats, J. W.; Ried, W. Synthesis 1990, 721.
- (14) (a) Mosby, W. L. In *Heterocyclic Systems with Bridgehead Nitrogen Atoms*; Wiley-Interscience: New York, **1961**.
 (b) Wiessberger, A.; Taylor, E. C. In *Special Topics in Heterocyclic Chemistry*; Wiley-Interscience: New York, **1977**.
- (15) Paudler, W.; Chao, C.; Helmick, L. J. Heterocycl. Chem 1972, 1157.
- (16) Petrich, S. A.; Qian, Z.; Santiago, L. M.; Gupton, J. T.; Sikorski, J. A. *Tetrahedron* **1994**, *50*, 12113.
- (17) Brown, D. J.; Nagamatsu, T. Aust. J. Chem. 1977, 30, 2515.
- (18) Krasovsky, A. L.; Nenajdenko, V. G.; Balenkova, E. S. *Tetrahedron* **2001**, *1*, 1349.

Downloaded by: East Carolina University. Copyrighted material.

- (19) Nenajdenko, V. G.; Krasovsky, A. L.; Lebedev, M. L.; Balenkova, E. S. Synlett 1997, 1349.
- (20) Krasovsky, A. L.; Nenajdenko, V. G.; Balenkova, E. S. *Synthesis* **2002**, in press.
- (21) Krasovsky, A. L.; Hartulyari, A. S.; Nenajdenko, V. G.; Balenkova, E. S. Syntheses 2002, 133.
- (22) Krasovsky, A. L.; Moiseev, A. M.; Nenajdenko, V. G.; Balenkova, E. S. *Khim. Het. Soedin* 2002, 253.
- (23) Krasovsky, A. L.; Moiseev A. M.; Nenajdenko, V. G.; Balenkova, E. S. *Khim. Het. Soedin* **2002**, in press.
- (24) Guerrel, P.; Jacquier, R.; Maury, G. J. J. Heterocycl. Chem. 1971, 8, 643.
- (25) Kawase, M.; Hirabayashi, M.; Saito, S.; Yamamoto, K. Tetrahedron Lett. 1999, 40, 2541.
- (26) Bouillon, J.-P.; Janousek, Z.; Viehe, H. G.; Tinant, B.; Declercq, J.-P. J. Chem. Soc., Perkin Trans. I 1995, 2907.